ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ: SCRX) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental new drug application (sNDA) for its new Sular formulation. The new Sular formulation utilizes SkyePharma’s (LSE:SKP) patented GeomatrixTM technology, which is designed to provide a lower dose of Sular for each of its current doses.
